February 22, 2022
Bad Homburg v.d.H.
Press Conference Full Year Results 2021, Fresenius and Fresenius Medical Care
Downloads
- Social-Media-Guidelines (deutsch) (PDF, 2.00 MB)
- Social Media Guidelines (english) (PDF, 1.97 MB)
- Guía de medios sociales (español) (PDF, 2.09 MB)
- Conseils d'utilisation des réseaux sociaux (français) (PDF, 1.85 MB)
- Richtlijnen voor sociale media (nederlands) (PDF, 1.85 MB)
- социальные медиа руководства (русский) (PDF, 223 KB)
Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, has conducted a study examining the effectiveness of the “Medical Patient Review continuous quality improvement” (MPR-CQI) program in 20 countries of the region Europe, Middle East and Africa (EMEA). The study has demonstrated, by means of mediation analysis, that improvements in medical key performance indicators (KPIs), occurring after the MPR-CQI program implementation, was associated with a significant reduction in mortality risk of about 30 percent in study participants.
For the development of the MPR-CQI program, the company used therapy data from more than 70,000 patients treated in Fresenius Medical Care’s EMEA NephroCare network to define, monitor and improve 10 KPIs – intermediate clinical endpoints – including hemoglobin, hydration status, hemodynamic status and infusion volume. The Medical Patient Review’s monthly review circles and evaluations of patients’ health indicators allow physicians to identify, prioritize and address patient’s medical needs.
“Delivering the highest quality care for people living with kidney disease is central to our mission, and data-driven insights are vital for ongoing clinical care improvement and innovation,” said Franklin W. Maddux, MD, Global Chief Medical Officer of Fresenius Medical Care. “The breadth and depth of our company’s clinical data, combined with our efforts in digital innovation and connected health, are generating a compelling evolution of clinical results.”
The quality performance of Fresenius Medical Care’s clinical governance strategy has been evaluated in an historical cohort study based on the company's own EuCliD database in the EMEA region. The company has published the study results in Nephrology, Dialysis & Transplantation, the official journal of the European Renal Association/European Dialysis and Transplant Association, to make them publicly available to the professional community and support further improvements in care worldwide: https://doi.org/10.1093/ndt/gfab160
The Medical Patient Review continuous quality improvement program is based on EuCliD data – Fresenius Medical Care’s digital patient care system- and enables the company to define evaluation processes involving medical and nursing experts. It also enables a detailed analysis of patients that allows a better understanding of medical needs, while providing intensive experiences from correlating improvements in medical and economic efficiency results – to deliver feedback focused on effective and efficient care. Through its digital patient care system, Fresenius Medical Care is planning to also enable third-party clients to benefit from the MPR.
As part of its 2025 growth strategy, Fresenius Medical Care is using digital technologies and artificial intelligence (AI) to develop new forms of kidney therapy. Physicians in more than 100 clinics in the company’s network can already use an AI-based algorithm that can help to improve renal anemia management while reducing drug-related costs. Fresenius Medical Care is planning to enrich the Medical Patient Review process by the MPR Advanced Benchmarking System which is based on an ensemble of 22 AI-based models that are designed to help detect best clinical practices, pinpoint high-performing centers beyond case-mix differences, discover emerging medical needs and set realistic margins of improvement for each intermediate clinical endpoint in all clinics.
The MPR Advanced Benchmarking System will be piloted starting this fall in NephroCare clinics in one EMEA country. Additional AI-based products for the management of non-dialysis dependent chronic kidney disease, vascular access care, home dialysis therapies and intradialytic complications are now being developed.
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.
Infusion therapy is the administration of medication intraveniously through a needle or catheter. Among the essential products are infusion solutions, medical devices, blood volume replacement solutions, and medical products such as rinsing solutions as well as intravenously-administered drugs.
Infusion solutions, for example, comprise electrolyte and glucose solutions as well as concentrated carbohydrate solutions, infusion solutions containing electrolytes and substrate solutions for drugs. Volume replacement solutions based on hydroxyethyl starch (HES) are used to increase plasma volume.
I.V. Drugs
Intravenous administration of drugs is indispensable today. A patient is administered drugs intravenously, meaning directly into a vein. This type of administration is used in cases of emergency, since the drug this way reaches the entire human body directly through the bloodstream and can be effective within a few seconds. Drugs are also administered intravenously in intensive care and during surgeries. Physicians decide to administer drugs via the vein particularly when patients are no longer able to take drugs orally or if the digestive tract no longer functions properly.
Fresenius Kabi offers a wide range of generic intravenously administered drugs. Primarily severely ill patients in hospitals are treated with these drugs – for example at emergency wards and intensive care units. Analgesics and anesthetics as well as antibiotics and antiinfectants are among these drugs.
Analgesics eliminate or decrease sensitivity to pain. Patients at emergency wards receive these preparations intravenously during or after surgical procedures.
Through intravenous anesthetics, such as Propofol, anesthesia can be induced or maintained. Furthermore, these drugs are used in intensive medicine for long-term sedation: Patients are put into an artificial coma to support their healing process. Fresenius Kabi also offers products for this application.
Antibiotics treat bacterial infections, which can have many different causes. Fresenius Kabi offers a large selection of different active ingredient categories. Among these are the most important antibiotic groups such as penicillins, cephalosporins and quinolones. Some of these products have a limited stability in liquid form and are therefore offered as sterile powder products, which are dissolved shortly before administration. Other substances are available as a ready-to-use solution in infusion bottles or infusion bags.
Other antiinfectants that Fresenius Kabi offers include drugs such as acyclovir that are used to treat viral infections.
In addition to these product groups, Fresenius Kabi offers drugs that are used to stabilize the cardiovascular function of patients receiving intensive and emergency care and to treat gastrointestinal problems.
Contact
Fresenius Kabi AG
Else-Kröner-Str. 1
61352 Bad Homburg
Germany
T: +49 6172 686-0
communication@fresenius-kabi.com
Fill out the fields and click "Show data". The Total Return Calculator will provide you with the current value of your Fresenius shares and the return. Moreover, the Calculator shows the share price performance during the selected period.
Contact
Vice President Investor Relations
Deputy Head of Investor Relations
T: +49 (0) 6172 608-5167
florian.feick@fresenius.com
Related Links
Interactive Tool
For blood donation and component processing, Fresenius Kabi offers medical devices. These include cell separators (apheresis systems), autotransfusion devices, blood bag and filter systems as well as related blood processing equipment. Component processing consists of the separation and collection of certain blood cells.
Blood Cell Separator
The Fresenius cell separator has three areas of application:
- Donate blood cells: obtaining cells from the blood of a donor for transfusion, for example for treating coagulation dysfunctions or leukemia patients
- Remove cancer cells: removing diseased cells or blood plasma from the blood of a patient with leukemia or an autoimmune disease, i. e., in patients with disorders where the body produces defense substances against its own cells
- Collect a patient’s cells: collecting cells from a patient's own blood for re-infusion, for example prior to operation.
A cell separator is primarily used to collect blood platelets or thrombocytes. While red blood cells mainly transport oxygen and other blood cells ward off pathogens, thrombocytes play an important role in blood clotting. Patients with too few thrombocytes suffer from an inability of the blood to coagulate properly. Injuries can lead to potentially dangerous bleeding. One example of the cause of thrombocyte deficiency is cancer therapy. Doctors infuse patients with healthy donor thrombocytes following treatment.
Thrombocytes are obtained most effectively with a blood cell separator. The machine, which works like a centrifuge, gently separates thrombocytes from the other blood components. Components that are not needed are immediately returned to the donor. Because only the thrombocytes are taken, which regenerate much quicker than red blood cells, a donor may donate much more frequently than in regular whole-blood donations. The cell separator also allows a much larger number of thrombocytes to be collected per donation than in whole blood. All patients who require a large number of thrombocytes can benefit double from the procedure – regular transfusions include thrombocytes from several sources but a blood cell separator can reduce the number of donors needed per transfusion. This allows a doctor to select thrombocytes from the most appropriate donors. This is important because the efficacy of the thrombocytes improves when the blood groups of donors and recipients match.
A cell separator can separate thrombocytes from other blood cells; it can also support the treatment of leukemia patients by removing diseased cells directly from the blood. Since leukemic cancer cells quickly reproduce, this procedure cannot heal a patient. But it relieves the strain on the kidneys by considerably lowering the number of destroyed cancer cells that must be removed from the blood following treatment.
Although rarely used, another application of the blood cell separator is quickly gaining in importance. Doctors can use the device to remove stem cells from the blood of a cancer patient. Through pre-treatment bone marrow stem cells start to reproduce and partially move into the blood stream. These stem cells can be collected almost like platelets. This way surgery to obtain stem cells directly from bone marrow can be avoided.
The treatment subsequently used to combat cancer cells damage the stem cells from which all other blood cells are made. If the patient receives healthy stem cells after chemotherapy, healthy blood cells can develop quicker, for example the platelets that are important for hemostasis and coagulation.
Blood bag systems
Blood bag systems are the foundation for worldwide blood supply by "classical" blood donation. More than 90 percent of all blood donations are processed in these systems that consist of up to six different bags with variable functions.
A combination of bags with venous cannulae and integrated needle protection, pre-donation sampling pouches and different filtration devices form the basis for highly professional whole blood collection systems. They allow producing different blood component preparations according to national and international standards. Blood donation and processing with these systems is supplemented by other devices such as automated scales and blood separators, sterile docking systems and sealers to name a few.
Contact
Fresenius Kabi AG
Else-Kröner-Str. 1
61352 Bad Homburg
Germany
T: +49 6172 686-0
communication@fresenius-kabi.com
Comprehensive patient care begins with prevention. Fresenius Helios' occupational healthcare centers offer a wide range of workplace prevention services. In addition, the Helios Prevention Center (HPC) of Fresenius Helios offers programs for individual prevention and company health management in the form of checkups and health coaching at numerous locations around Germany.
Occupational Healthcare
The aim of effective occupational healthcare is to maintain and promote health, prevent harmful influences resulting from working life, detect illnesses and damage to health at an early stage, as well as reintegrate employees into the workplace after a longer period of absence due to illness.
In Germany, Helios offers fully comprehensive occupational medical care with a fixed, permanent contact person at 17 occupational healthcare centers. This covers everything from legally required examinations, health protection and promotion to risk assessments and recommendations for optimal workplace design.
Spain's leading occupational risk prevention companies Fraterprevención, MC Prevención, Premap and Unipresalud complement the Quirónsalud network, with more than 150 centers throughout Spain and a presence in Latin America and the Middle East.
Helios Prevention Center (HPC)
A check-up at the Helios Prevention Center provides an accurate picture of one's own state of health. Our participants at one of our six locations benefit from short waiting times, short distances and holistic lifestyle advice.
The HPC qualifies participants to handle health issues with confidence and enables them to achieve a performance grade that can function as a model. Health conscious and competent leadership can act as a beacon to bind together and motivate employees. HPC views itself as a partner to companies that want to actively promote the health of their employees. From a one-day checkup at a Helios clinic to health workshops lasting several days at beautifully situated resorts – our modular program combines Helios quality with the ambience of exclusive hotels. Studies show occupational healthcare measures generate outstanding cost-benefit ratios.
Contact
Helios Prevention Center
Service-Hotline: 0800-633 49 46
info@helios-preventioncenter.de
Related Links
Fresenius Helios
Fresenius Vamed is a leading global provider of services for hospitals and other healthcare facilities. Its portfolio ranges from project development and planning to the total operational management of healthcare facilities and providing services to patients. The services are aimed at various areas of healthcare, ranging from prevention to acute care, rehabilitation, and nursing.
Headquartered in Vienna, Austria, Fresenius Vamed has successfully completed more than 1,000 healthcare projects in 101 countries on five continents since the company’s founding in 1982.
VAMED Value Chain
Project business:
- Project development
- Planning
- Project management and construction
Service business:
- Services (technical, commercial, infrastructural)
- Operational management (technical Management, total operational management)
The project business comprises the consulting, project development, planning, turnkey construction, and financing management of projects. VAMED responds flexibly to the local needs of clients, providing custom-tailored solutions all from one source. The company also carries out projects in cooperation with partners. Among public clients there is growing interest in public-private partnership (PPP) models. With 25 of these models, VAMED is a pioneer in this market segment.
VAMED offers a full range of facility management services for healthcare facilities. Modular in design, the company's service offering encompasses every aspect of technical, commercial, and infrastructural facility management. This ranges from building and equipment maintenance, medical technology management, and technical management through to the operational management. Its integrated portfolio of services is aimed at the optimal operation of a healthcare facility. VAMED was responsible for the total operational management of about 100 healthcare facilities on five continents with more about 18,000 beds. Worldwide, VAMED provides technical operation services to more than 840 hospitals with about 227,000 beds.
VAMED Vitality World’s thermal spa and wellness resorts have succeeded in bridging the gap between preventive medicine and healthcare tourism. With more than 3 million visitors annually in nine thermal spas and wellness resorts, VAMED is the market leader in Austria.
Vamed belongs to Fresenius SE & Co. KGaA healthcare group with a stake of about 77 percent and is one of the two Investment Companies of Fresenius.
Contact
VAMED Aktiengesellschaft
Sterngasse 5
1230 Vienna
Austria
office@vamed.com
+43 1 601 27-0
Fresenius Helios is the leading private healthcare provider in Europe serving with around 140 clinics and numerous outpatient facilities about 27 million people annually. Together with Fresenius Kabi, a provider of healthcare products for the critically and chronically ill, Fresenius Helios is part of the Fresenius healthcare group. With its 130,000 employees of the Helios Group in Germany and Quirónsalud in Spain and Latin America, Fresenius Helios generated total sales of more than 13.5 billion euros in 2025.
Helios Germany operates more than 80 hospitals, about 200 outpatient care centers with, six prevention centers and 30 occupational medicine centers. Helios treats approximately 5.6 million patients annually, of whom 4 million are outpatients. Since its beginnings, Helios has focused on measurable, high medical quality as well as data transparency and is better than the German average in more than 90 percent of the quality targets. With about 80,000 employees, Helios generated sales of €8.1 billion in 2025. With its own 35 training centers, Helios represents education and training in the healthcare sector. Helios Germany is headquartered in Berlin.
Quirónsalud has 57 hospitals, including seven in Latin America, around 130 outpatient centers and more than 300 occupational risk prevention centers, and treats approximately 22 million patients annually, of whom 20 million are outpatients. Quirónsalud has about 50,000 employees and generated sales of more than €5.4 billion in 2025.
Contact
Helios Kliniken GmbH
Friedrichstr. 136
10117 Berlin
Germany
T +49 30 521 321-0